SAB Biotherapeutics (SABS) Income from Non-Controlling Interests (2021 - 2024)
SAB Biotherapeutics (SABS) posted Income from Non-Controlling Interests of $67000.0 for Q2 2024, down 1.47% on a QoQ basis from $68000.0 in Q1 2024, and down 5.63% year-over-year from $71000.0 in Q3 2023.
SAB Biotherapeutics (SABS) Income from Non-Controlling Interests (2021 - 2024) Analysis & Trends
SAB Biotherapeutics' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at $67000.0 for Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Dec 31, 2023 | -210,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 71,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | -214,000.00 |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 71,000.00 |
| Mar 31, 2022 | 72,000.00 |
| Dec 31, 2021 | -228,000.00 |
| Sep 30, 2021 | 78,000.00 |
| Jun 30, 2021 | 74,000.00 |
| Mar 31, 2021 | 75,000.00 |